[go: up one dir, main page]

EP2501365A2 - Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires - Google Patents

Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires

Info

Publication number
EP2501365A2
EP2501365A2 EP10781842A EP10781842A EP2501365A2 EP 2501365 A2 EP2501365 A2 EP 2501365A2 EP 10781842 A EP10781842 A EP 10781842A EP 10781842 A EP10781842 A EP 10781842A EP 2501365 A2 EP2501365 A2 EP 2501365A2
Authority
EP
European Patent Office
Prior art keywords
capsule according
pharmaceutical
pharmaceutical capsule
microcapsules
group formed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10781842A
Other languages
German (de)
English (en)
Inventor
Antonio PARENTE DUEÑA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GP Pharm SA
Defiante Farmaceutica SA
Original Assignee
GP Pharm SA
Defiante Farmaceutica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GP Pharm SA, Defiante Farmaceutica SA filed Critical GP Pharm SA
Publication of EP2501365A2 publication Critical patent/EP2501365A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to a pharmaceutical composition in the form of a capsule which comprises a suspension of polymeric microcapsules suspended in an oil which contains polyunsaturated fatty acid alkyl esters (PUFA), wherein the microcapsules contain at least one polymer and one active pharmaceutical ingredient, and its use for the treatment and/or prevention of cardiovascular diseases.
  • PUFA polyunsaturated fatty acid alkyl esters
  • ACE inhibitors angiotensin-converting enzyme inhibitors
  • ARB angiotensin II receptor blockers
  • ACE inhibitors and ARBs act on the renin-angiotensin system.
  • ACE inhibitors inhibit the angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II. They are very effective anti-hypertensive agents which are also used for the treatment of heart failure and myocardial infarction.
  • the majority of ACE inhibitors are administered with the carboxyl group in alpha position with regards to the secondary amino group in the form of diethyl ester, although its acids are the biologically active form.
  • the ARBs act by blocking the angiotensin II receptor in the arteries, preventing its action. Therefore, the ARBs are also a first-line treatment for hypertension, particularly in the case of patients who develop cough due to ACE inhibitors. ARBs are also used for the treatment of heart failure and diabetic nephropathy.
  • PUFA Polyunsaturated fatty acids
  • PUFAs are essential fatty acids and should be obtained from a person's diet. They are divided into omega-3 and omega-6 fatty acids depending on the position of the first unsaturation (n-3 and n-6 respectively).
  • the principal omega-3 fatty acids are found in fish oils, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • PUFAs can be found in the form of triglycerides or alkyl esters. Commercial compositions of omega-3 fatty acid alkyl esters vary in purity and content of fatty acids and are normally expressed in relation to the content in EPA and DHA. PUFAs, in any of their forms, are easily oxidized and should be stored under an inert atmosphere and protected from light. Commercial compositions contain antioxidants to minimize their degradation.
  • ACE inhibitors can suffer from three types of degradation: a) internal cyclization to form diketopiperazines, b) hydrolysis of the ester group of the side chain to give the diacid, and c) oxidation that produces unwanted colored products. Degradation occurs both in liquid and solid state.
  • WO 2008/000040 A1 and WO 2008/001 184 A2 the choice of the different excipients can affect the stability of ramipril and other ACE inhibitors such as quinapril, enalapril or spirapril, accelerating their degradation; furthermore, a significant cause of decomposition is mechanical stress associated with the manufacturing process.
  • water scavenger compounds can be incorporated in the formulation, such as copovidone in the case of cilazapril.
  • Fosinopril is unstable since it is susceptible to hydrolytic degradation in the ester and phosphodiester groups, and the same occurs with the trandolapril ester group; in EP 1906931 B1 the compositions of these two active ingredients are stabilized with dimethicone, so that cyclization, hydrolysis and/or oxidation are inhibited.
  • the approaches to the stabilization of pharmaceutical compositions which contain ACE inhibitors that do not use the addition of stabilizing excipients would be those which use polymer coatings, such as polymer coatings of agglomerate [US 5151433 A] or of individual particles of ramipril in the final solid formulation [WO 2006/050533 A2], or coating an inert nucleus with the active ingredient itself [US 2005202081 A1] that would avoid degradation induced both by the mechanical stress of compression and the contact of the active ingredient with potentially incompatible excipients.
  • Some ARBs also show formulation problems, it being necessary to avoid the presence of water according to that deduced from the formulations described in the literature for valsartan [EP 1674080 A1].
  • Irbesartan, valsartan (both bulky powders) and candesartan cilexetil (sticky), for example, are very difficult to formulate in tablets or capsules due to the physical properties of the solids [EP 0747050 B1 , EP 1774967 A1 , WO 2008/012372 A1].
  • Candesartan cilexetil is stable with regards to temperature, moisture and light when it is isolated, but it decomposes over time when it is formulated with excipients in tablets.
  • the principal product of degradation is the derivative O-desethyl.
  • This degradation caused by pressure, abrasion and heat applied during the granulation or high pressure molding process can be reduced through the incorporation in the formulation prior to the compression of oily substances with a low melting point [EP 0546358 B1], of lipids or phospholipids [WO 2005/079751 A2], of different co-solvents [WO 2005/070398 A2], of carbohydrates for the formation of adsorbates of the active ingredient [EP 1952806 A1], of water soluble polymers [WO 2005/084648 A1] or of methacrylate polymers with the amorphous active ingredient [EP 1997479 A1].
  • Gelatin capsules whether they are hard or soft, allow the active pharmaceutical ingredients to be incorporated into their interior, but the protection of the active ingredient is not satisfactory in the event that the substance is degradable or unstable in the presence of moisture or oxidizing agents.
  • Conventional gelatin capsules possess an external layer whose basic ingredient is gelatin, and in general this capsule can be hard or soft, the latter containing plasticizers.
  • the coating of the conventional gelatin capsules consists of a single external layer, with a uniform thickness and composition, which covers the inside, which contains the active pharmaceutical ingredient mixed with the appropriate excipients.
  • the content of the soft gelatin capsules is normally liquid or semi-liquid: oils, polar liquids, microemulsions, suspensions, waxes or colloids. The content in water of the liquid inside cannot exceed 20% so that it does not dissolve the gelatin layer.
  • the external layer of the capsule contains a certain amount of water as an ingredient.
  • water in the coating of the conventional gelatin capsules constitutes a serious problem, in the case that the active pharmaceutical ingredients or their salts to be formulated are water soluble, degradable in the presence of moisture or unstable in contact with water.
  • the active pharmaceutical ingredient contained in the capsule coming into contact with the moisture of the gelatin mass of the outside layer, whether this is during the production process or during the storage process of the finished capsules, due to the partial diffusion of the water of the coating towards the inside of the capsule, or due to the contact of a part of the active ingredient with the capsule walls.
  • the outer coating of the capsule contains, as well as water, a notable quantity of conventional additives such as plasticizers, colorants, opacifiers and preservatives, it is also very difficult to satisfactorily prevent or control the possible incompatibilities between these and the active ingredient.
  • additives can facilitate the oxidation, degradation or hydrolysis processes, causing a loss of activity of the active ingredient formulated [EP 0769938 B1].
  • Another factor to take into account is the possible chemical interaction between the content and gelatin in the capsule, which may favor cross-linking and thus reduce the capsule's solubility in the aqueous medium (delaying its speed of disintegration).
  • EP 0769938 B1 there are described one or more hydrophobe polymer layers under the gelatin layer, as well as silicone resins in the inside of the capsule.
  • the active ingredient which can be an ACE inhibitor, or an anticholesterol agent such as omega-3 fatty acid eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), among others, are found on the inside, mixed, dissolved, suspended or bound in the silicone resin.
  • EPA omega-3 fatty acid eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • formulations based on lipids increase the bioavailability of certain active pharmaceutical ingredients.
  • examples of formulations which increase bioavailability of the active ingredients through the use of PUFA are described in the literature, generally by the formation of emulsions. Therefore, in US 5447729 A a release system is proposed which consists of an emulsion or dispersion of particles of an active ingredient, which can be an ACE inhibitor, among others, that alternate different hydrophobic and hydrophilic layers; the emulsion can be incorporated onto capsules or tablets, and for its formulation long chain fatty acids such as linolenic, linoleic or arachidonic acids are used.
  • WO 2006/135415 A2 the preparation of microemulsions formed by nanoparticles of acids such as eicosapentaenoic acid (EPA) are described, which contain active pharmaceutical ingredients such as ACE inhibitors or ARBs, among others. In all these cases the contact with water or excipients of the formulation would not be avoided, which is a cause of degradation for many active ingredients.
  • EPA eicosapentaenoic acid
  • candesartan cilexetil is stabilized in tablets through the addition of lipids or phospholipids to the composition.
  • the lipids can be fatty acids such as linoleic and/or arachidonic acid, or their glyceryl esters.
  • WO 2007/103557 A2 it proposed as a solution to the problems of chemical incompatibilities in compositions with two or more active pharmaceutical ingredients, the physical separation of the components in a gelatin capsule, hard or soft, which contains a first active ingredient such as the omega-3 fatty acids, with one or more capsule coatings wherein at least one of them consists of a polymer combined with another active ingredient such as enalapril, and the coating which contains this active ingredient is isolated from the capsule and optionally from the outside by additional coatings.
  • the manufacturing process is complex due to the fragility and solubility in water of the gelatin coatings and requires a rigorous control of the temperature and speed of deposition during coating.
  • WO 2006/081518 A2 in order to achieve a modified release of multiple active ingredients, among them antihypertensive agents, complexes of the active ingredients with ion exchange resins are prepared, with or without polymeric coatings, suspended in a non-ionic and non-aqueous vehicle ("NINA" vehicle) such as alcohols, polyols, oils, triglycerides or waxes, among them omega-3.
  • NINA non-ionic and non-aqueous vehicle
  • the active pharmaceutical ingredient must contain an acid or basic functional group in order to be able to form the complex.
  • the application of these formulations is solely by topical route.
  • the use of resinates for oral administration is controversial, since the administration of large quantities of ion exchange resins or their prolonged use in chronic treatments can change the ionic force of the gastrointestinal fluids and cause electrolyte imbalances.
  • many of the references described represent an attempt to solve the problems of instability associated with the pharmaceutical compositions which contain ACE inhibitors and/or ARBs, the problem arising from the technique is the need to improve the stability of these pharmaceutical compositions, especially in the presence of moisture.
  • the solution proposed by this invention is a pharmaceutical capsule which incorporates alkyl esters of PUFA and microcapsules of the desired active ingredient which is isolated by means of a polymer.
  • the subject-matter of this invention is a pharmaceutical composition in the form of a capsule which provides a greater protection for active pharmaceutical ingredients against moisture, oxidizing agents and/or the possible chemical interactions with the additives of the exterior coating.
  • the pharmaceutical capsule of the invention allows active pharmaceutical ingredients known for their instability to be conveniently formulated, such as the angiotensin-converting enzyme inhibitors (ACE inhibitors) and/or the angiotensin II receptor blockers (ARB), avoiding its degradation through the isolation provided by the combination of a polymer coating of the active pharmaceutical ingredient and its suspension in alkyl esters of PUFA.
  • ACE inhibitors angiotensin-converting enzyme inhibitors
  • ARB angiotensin II receptor blockers
  • this invention relates to a new pharmaceutical composition which avoids the problems of degradation of active pharmaceutical ingredients such as the angiotensin- converting enzyme inhibitors (ACE inhibitors) and/or the angiotensin II receptor blockers (ARB) when they are formulated in pharmaceutical capsules for oral administration.
  • active pharmaceutical ingredients such as the angiotensin- converting enzyme inhibitors (ACE inhibitors) and/or the angiotensin II receptor blockers (ARB) when they are formulated in pharmaceutical capsules for oral administration.
  • this invention relates to a pharmaceutical capsule which comprises a suspension of polymer microcapsules which comprise at least one polymer and active pharmaceutical ingredient selected from the group formed by the ACE inhibitors and the ARBs, these microcapsules are suspended in an oil which contains polyunsaturated fatty acid alkyl esters.
  • the polymer of the microcapsules constitutes their external part and provides a complete coating for the active pharmaceutical ingredient in the capsule.
  • the active pharmaceutical ingredients are found inside the polymer microcapsules in suspension in an oil which contains alkyl esters of PUFA.
  • the active pharmaceutical ingredients are isolated both from the exterior medium and the alkyl esters of PUFA through the polymer, which disintegrates easily in the gastrointestinal medium.
  • the pharmaceutical capsule of the invention allows, as well as the joint administration of active pharmaceutical ingredients in a combination therapy, the active pharmaceutical ingredient to be isolated from moisture and capsule coating additives, as well as moisture and oxygen from the outside.
  • the polymer coating provides stability to the active pharmaceutical ingredients, avoiding the formation of degradation products caused by moisture, compression and high temperatures during the preparation process of the final composition in the form of pharmaceutical capsules.
  • the fatty acids of the alkyl esters of PUFA belong to the omega-3 series.
  • the PUFAs are selected from the group formed by the (all-cis)-5,8,' ⁇ 1 ,14,17- eicosapentaenoic or eicosapentaenoic (EPA) or timnodonic acid or icosapent (C20:5 n-3), the (a//-c/ ' s)-4,7,10, 13,16, 19-docosahexaenoic or docosahexaenoic (DHA) or cervonic acid or doconexent (C22:6 n-3), and/or mixtures thereof, such as Omacor ® , Lovaza ® or Zodin ® , among others.
  • the EPA:DHA relationship can range between 100:0 and 0:100, preferably between 4:1 and 1 :4, and more preferably between 1 :2 and
  • the alkyl radical of the alkyl esters of PUFA is selected from the group formed by short chain alkyl radicals, with from 1 to 8 carbon atoms.
  • the alkyl radical is selected from the group formed by ethyl, methyl, propyl, butyl and/or mixtures thereof. More preferably, the alkyl radical is an ethyl group.
  • the oil containing alkyl esters of PUFA is an oil enriched in alkyl esters of PUFA, preferably, the oil contains more than 50% of alkyl esters of PUFA, more preferably more than 60% of alkyl esters of PUFA and even more preferably, more than 85% of alkyl esters of PUFA.
  • the quantity of alkyl esters of PUFA contained in the pharmaceutical capsule of the invention is comprised between 0.01 and 4 g, preferably between 0.1 and 2 g.
  • the active pharmaceutical ingredient is an angiotensin- converting enzyme inhibitor, selected, without restriction, from the group formed by captopril, enalapril, enalaprilat, ramipril, quinapril, perindopril, lisinopril, benazepril, fosinopril, spirapril, trandolapril, moexipril, cilazapril, imidapril, rentiapril, temocapril, alacepril, delapril, moveltipril, zofenopril, pentopril, libenzapril, pivopril, ceronapril, indolapril, teprotide, their pharmaceutically acceptable salts and their acids.
  • an angiotensin- converting enzyme inhibitor selected, without restriction, from the group formed by captopril, enalapril, enalaprilat, ramipri
  • the active pharmaceutical ingredient is an angiotensin II receptor blocker, selected, without restriction, from the group formed by candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, tasosartan, pratosartan, azilsartan, saralasin, ripisartan, elisartan, milfasartan, embusartan, fonsartan, saprisartan, zolasartan, forasartan, pomisartan, abitesartan, fimasartan, W-benzyl-losartan, enoltasosartan, glycyl-losartan, opomisartan, trityl- losartan, sarmesin, isoteolin and their pharmaceutically acceptable salts.
  • an angiotensin II receptor blocker selected, without restriction, from
  • the polymer of the microcapsules of the pharmaceutical capsule of this invention is selected, without restriction, from the group formed by proteins, polysaccharides, polyesters, polyacrylates, polycyanoacrylates, polyethylene glycol and/or mixtures thereof.
  • the polymer of the microcapsules is selected from the group formed by gelatin, albumin, alginates, carrageenans, pectins, gum arabic, chitosan, carboxymethylcellulose, ethylcellulose, hydroxypropyl methylcellulose (HPMC), nitrocellulose, cellulose' acetate butyrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate-succinate, polyvinyl acetate phthalate, poly(E-caprolactone), poly(p-dioxanone), poly(5-valerolactone), poly(p-hydroxybutyrate), poly(p-hydroxybutyrate) copolymers and ⁇ -hydroxyvaler
  • the polymer is formed by copolymers of methacrylic acid (Eudragit ® L and S), polymers and copolymers of lactic and glycolic acids, polymers and copolymers of lactic and glycolic acids and polyethylene glycol, and/or mixtures thereof.
  • methacrylic acid Eudragit ® L and S
  • polymers and copolymers of lactic and glycolic acids polymers and copolymers of lactic and glycolic acids and polyethylene glycol, and/or mixtures thereof.
  • the polymer of the microcapsules of the pharmaceutical capsule of this invention can comprise a plasticizer additive.
  • the plasticizer additive is selected, without restriction, from the group formed by alkyl esters of the citric acid such as triethyl citrate, tributyl citrate, acetyl tributyl citrate and acetyl triethyl citrate, phthalates such as butyl phthalate and diethyl phthalate, glycerin, sorbitol, maltitol, propylene glycol, polyethylene glycol, glucose, sucrose, lanolin, palmitic acid, oleic acid, stearic acid, metal salts of fatty acids such as stearic acid or palmitic acid, sodium stearate, potassium stearate, propylene glycol monostearate, acetylated monoglycerides such as monoacetylated glycerin and glyceryl triacetate or triacetin, gly
  • fluidifying agents such as talc, colloidal silicon dioxide, glycerin, polyethylene glycol, glycerin monostearate and/or metal stearate salts.
  • the pharmaceutical capsule of this invention comprises at least one antioxidant, such as and not restricted to, butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), tert-butylhydroquinone (TBHQ), gallic acid esters such as propyl gallate, tocopherols such as vitamin E acetate, ascorbic acid esters such as ascorbyl palmitate and ascorbyl acetate, carnitine and/or mixtures thereof.
  • BHT butylhydroxytoluene
  • BHA butylhydroxyanisole
  • TBHQ tert-butylhydroquinone
  • gallic acid esters such as propyl gallate
  • tocopherols such as vitamin E acetate
  • ascorbic acid esters such as ascorbyl palmitate and ascorbyl acetate
  • carnitine and/or mixtures thereof preferably, the antioxidant is vitamin E acetate.
  • the microcapsules represent between 0.001% and 80% of the total weight of the pharmaceutical capsule of this invention, preferably between 0.01% and 60%, and more preferably between 0.1 % and 50% of the total weight of the pharmaceutical capsule of this invention.
  • the amount of active pharmaceutical ingredient incorporated in these microcapsules is comprised between 1% and 80% in weight, preferably between 1% and 60% in weight with respect to the total weight of the microcapsules.
  • the total amount of active pharmaceutical ingredient included in the pharmaceutical capsule of this invention depends on the recommended daily doses.
  • the pharmaceutical capsule of this invention can be a hard or soft capsule, of gelatin or any usual polymer in the preparation of capsules in the pharmaceutical industry, such as and not restricted to, hydroxypropyl methylcellulose (HPMC), pullulan, modified starches, carrageenans and/or mixtures thereof.
  • HPMC hydroxypropyl methylcellulose
  • the capsule is a gelatin capsule. More preferably, this capsule is made of soft gelatin.
  • the capsule has an enteric coating.
  • the capsule coating can contain other additives such as plasticizers, colorants, pigments, opacifiers, preservatives, moisturizers, surfactants, sweeteners and/or flavorings.
  • the preparation of the capsule is carried out through the usual procedures in the pharmaceutical industry, and can be any form and size known by the person skilled in the art.
  • microcapsules can be carried out by following any of the procedures described in the literature. As a description and not restricted to them, the different procedures for obtaining microcapsules can be grouped in the following sections:
  • a solution of the polymer together with its possible additives is prepared in an appropriate solvent.
  • the active pharmaceutical ingredient to be encapsulated is suspended and a solvent in which the polymer is not soluble is added to force the polymer deposition on the crystals of the active ingredient. Examples of these procedures can be found in documents such as ES
  • the active pharmaceutical ingredient to be encapsulated is dissolved in water or in a solution of another coadjuvant and is emulsified in a solution of the polymer and additives in an appropriate solvent such as dichloromethane.
  • the resulting emulsion is in turn emulsified in water or in an aqueous solution of an emulsifier such as polyvinyl alcohol.
  • an emulsifier such as polyvinyl alcohol.
  • the active pharmaceutical ingredient to be encapsulated, the polymer and the additives are jointly dissolved in an appropriate organic solvent.
  • This solution is emulsified in water or in a solution of an emulsifier such as polyvinyl alcohol and the organic solvent is eliminated by evaporation or extraction.
  • the resulting microcapsules are recovered by filtration or drying. Examples of these procedures can be found in documents such as US 5445832 A.
  • the active pharmaceutical ingredient to be encapsulated, the polymer and the additives are jointly dissolved in an appropriate solvent. This solution is evaporated and the resulting residue is micronized to obtain the suitable size, or it is dried by spray-drying. Examples of this procedure can be found in documents such as GB 2209937 A.
  • cardiovascular diseases are selected from the group formed by hypertension, heart failure and myocardial infarction.
  • cardiovascular diseases which comprises the administration of the pharmaceutical capsule of the invention.
  • the cardiovascular diseases are selected from the group formed by hypertension, heart failure and myocardial infarction.
  • Example 1 Preparation of pharmaceutical capsules which contain ramipril microcapsules with gelatin through simple coacervation procedures.
  • a 1 % solution of gelatin in water was prepared. 100 ml_ of this solution were taken and 1 g of ramipril powder was dispersed in it. Then 30 ml_ of saturated sodium sulfate solution in water were added. The mixture was stirred for 1 hour and 0.5 mL of 50% glutaraldehyde solution in water were added.
  • microcapsules formed by filtration were collected, washed with water and dried in a vacuum drying oven. Trie ramipril content of these microcapsules was 35%.
  • the resulting microcapsule powder was dispersed directly in oil containing a minimum of 90% of ethyl esters of PUFA, with a minimum EPA/DHA content of 85% in a ratio of 1.2:1 (719 mg of the suspension of microcapsules obtained per 100 g of oil). Next, 1.00 g of the dispersion of microcapsules in oil was incorporated to a soft gelatin capsule to obtain a dose of 2.5 mg of ramipril per capsule.
  • Example 2
  • Solution A A 10% solution in dichloromethane (DCM) of PLGA with an intrinsic viscosity (I.V.) of 0.17 and a lactic/glycolic ratio of 1 :1 was prepared.
  • DCM dichloromethane
  • Solution B 5 g of trandolapril and 1 g of vitamin E acetate were dissolved in 100 mL of solution A.
  • Solution C A 1 % solution of polyvinyl alcohol (PVA) in water was prepared.
  • Example 4 Preparation of pharmaceutical capsules which contain lisinopril microcapsules with poly(lactic-co-glycolic acid) (PLGA) prepared by the triple emulsion method.
  • Solution A 5 g of PLGA with an intrinsic viscosity (I.V.) of 0.4 dL g and a lactic/glycolic ratio of 1 :1 were dissolved in 50 mL of dichloromethane (DCM).
  • DCM dichloromethane
  • Solution B 1.08 g of lisinopril dihydrate were dissolved in 10 mL of water.
  • Solution C A 0.5% p/v concentration solution of polyvinyl alcohol (PVA) in water was prepared.
  • aqueous phase (solution B) was emulsified in the solution of PLGA (solution A) with the help of an Ultra Turrax homogenizer (W/O emulsion).
  • the previously prepared W/O emulsion was added to 1 L of the PVA solution (solution C) under intense stirring.
  • the new emulsion formed was stirred whilst a nitrogen current was passed through the reactor at a flow no less than 50L/minute to evaporate the DCM.
  • the microcapsules were recovered by filtration through a membrane with a pore diameter of 5 pm, they were washed with abundant water to eliminate the excess of PVA and were dried by lyophilization.
  • the microcapsule powder obtained contained 16%. of lisinopril, and was directly dispersed in oil containing a minimum of 90% of ethyl esters of PUFA, with a minimum EPA/DHA content of 85% in a ratio of 1.2:1 (1.59 g of the microcapsule suspension obtained per 100 g of oil). Next, 1.00 g of the microcapsule dispersion in oil was incorporated to a soft gelatin capsule, to obtain a dose of 2.5 mg of lisinopril per capsule.
  • Example 4 Preparation of pharmaceutical capsules that contain microcapsules of candesartan cilexetil with gelatin and carboxymethyl cellulose prepared by a complex coacervation procedure.
  • Solution A A 1 % solution of gelatin in water was prepared and the pH was adjusted so it was equal or higher than 7.
  • Solution B Another 1% solution of sodium carboxymethyl cellulose in water was prepared and the pH was adjusted so it was equal or higher than 7.
  • microcapsule powder which contained 40% of candesartan cilexetil.
  • This microcapsule powder was directly dispersed in oil containing a minimum of 90% of ethyl esters of PUFA, with a minimum EPA/DHA content of 85% in a ratio of 1.2:1.
  • the dispersion of microcapsules in oil obtained was incorporated to a soft gelatin capsule.
  • the quantities used to prepare the capsules of different size and doses of candesartan cilexetil are shown in Table 2.
  • Example 5 Preparation of pharmaceutical capsules which contain valsartan microcapsules and a methacrylic acid copolymer. 10 g of valsartan were suspended in 100 mL of a suspension of Eudragit FS 30D ® (suspension in water of 30% methacrylic acid, methyl methacrylate and methyl acrylate copolymers) until a fine suspension was obtained. Triethyl citrate was added to this suspension (polymer plasticizer) until a concentration of 5%.
  • the resulting suspension was dried by spray-drying, to give a microcapsule powder which contained 22% of valsartan.
  • microcapsule powder was directly dispersed in oil containing a minimum of 65% of ethyl esters of PUFA, with a minimum EPA/DHA content of 45% in a ratio of 1.2:1 (25.0 g of the suspension of microcapsules obtained per 100 g of oil).
  • 1.00 g of the microcapsule dispersion in oil was incorporated to a soft gelatin capsule, to obtain a dose of 40 mg of valsartan per capsule.
  • the percentages of the active pharmaceutical ingredient in the capsules were determined through HPLC after storage in amber glass containers for 1 month, 2 months, 3 months and 4 months. The percentages of the active pharmaceutical ingredient are shown in Table 3.
  • the stability of PUFAs was also studied (concentration of alkyl esters of EPA and DHA, as well as the EPA/DHA ratio) through gas chromatography, although no variations were observed in the composition.
  • Valsartan (example 5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique se présentant sous la forme d'une capsule qui contient des esters d'alkyle d'acides gras polyinsaturés (PUFA) et des principes actifs pour le traitement et/ou la prévention de maladies cardiovasculaires.
EP10781842A 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires Withdrawn EP2501365A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931024A ES2364011B1 (es) 2009-11-20 2009-11-20 Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
PCT/EP2010/007025 WO2011060945A2 (fr) 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
EP2501365A2 true EP2501365A2 (fr) 2012-09-26

Family

ID=43498490

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10781842A Withdrawn EP2501365A2 (fr) 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires

Country Status (14)

Country Link
EP (1) EP2501365A2 (fr)
JP (1) JP2013511480A (fr)
KR (1) KR20120117986A (fr)
CN (1) CN102711735A (fr)
AR (1) AR079428A1 (fr)
AU (1) AU2010321248A1 (fr)
BR (1) BR112012011902A2 (fr)
CA (1) CA2781434A1 (fr)
ES (1) ES2364011B1 (fr)
IL (1) IL219874A0 (fr)
MX (1) MX2012005744A (fr)
RU (1) RU2012122886A (fr)
TW (1) TW201141469A (fr)
WO (1) WO2011060945A2 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (es) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (fr) 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
WO2013167993A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques dégénératifs
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013167999A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement d'affections neurologiques
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168011A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur chronique
WO2013168012A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles respiratoires
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur fibromyalgique
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013175347A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de troubles respiratoires
CN104603097A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗多发性硬化症的组合物和方法
WO2013175344A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
WO2013175376A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes de traitement de la douleur locale
WO2013175377A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de la mucosite
AU2013264894B2 (en) 2012-05-23 2015-11-19 Cellix Bio Private Limited Compositions and methods for treatment of inflammatory bowel disease
KR101414873B1 (ko) * 2012-06-28 2014-07-03 보령제약 주식회사 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
KR101391551B1 (ko) * 2012-07-10 2014-05-02 보령제약 주식회사 심부전증 예방, 완화 및 치료용 약학 조성물 및 이를 포함하는 복합제제
WO2014020480A2 (fr) 2012-08-03 2014-02-06 Mahesh Kandula Compositions et méthodes pour le traitement de la migraine et de maladies neurologiques
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
WO2014041445A2 (fr) * 2012-09-13 2014-03-20 Mahesh Kandula Compositions et procédés pour le traitement de l'hypertension et la gestion de la néphropathie diabétique
CN102895205A (zh) * 2012-11-09 2013-01-30 重庆市力扬医药开发有限公司 一种快速溶出的阿齐沙坦药物制剂
FR3002735B1 (fr) * 2013-03-04 2015-07-03 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
FR3002736B1 (fr) 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
WO2014142607A1 (fr) * 2013-03-14 2014-09-18 보령제약 주식회사 Médicament combiné pharmaceutique
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
RU2558855C1 (ru) * 2014-04-15 2015-08-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Способ получения микрокапсул лозартана калия в альгинате натрия
RU2577685C1 (ru) * 2014-09-19 2016-03-20 Александр Александрович Кролевец Способ получения нанокапсул лозартана калия в альгинате натрия
EP3240779B1 (fr) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions et méthodes de traitement de l'épilepsie et de troubles neurologiques
WO2016051420A1 (fr) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions et méthodes pour le traitement de la sclérose en plaques
RU2605848C2 (ru) * 2014-10-10 2016-12-27 Александр Александрович Кролевец Способ получения нанокапсул лекарственных препаратов группы цефалоспоринов в интерфероне
WO2016098119A1 (fr) 2014-10-27 2016-06-23 Cellix Bio Private Limited Sels ternaires d'ester monométhylique d'acide fumarique associés à la pipérazine ou à l'éthylènediamine pour le traitement de la sclérose en plaques
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
RU2596476C1 (ru) * 2015-04-27 2016-09-10 Александр Александрович Кролевец Способ получения нанокапсул лекарственных растений, обладающих спазмолитическим действием
JP6298435B2 (ja) * 2015-10-28 2018-03-20 大原薬品工業株式会社 アンジオテンシンｉｉ受容体拮抗薬を含有する口腔内崩壊錠
CN106074542A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐软胶囊的制备方法
KR101914051B1 (ko) * 2018-07-13 2018-12-28 (주)바이오제닉스 숯이 함유된 이중 캡슐 및 이의 제조방법
CN114617264A (zh) * 2020-12-14 2022-06-14 深圳市前海小藻科技有限公司 具有高含量epa的植物胶囊制剂
JPWO2022145443A1 (fr) * 2020-12-28 2022-07-07

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (fr) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
HU222489B1 (hu) 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
TW284688B (fr) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
ES2242398T3 (es) 1998-06-05 2005-11-01 Warner-Lambert Company Llc Estabilizacion de composiciones que contienen inhibidores de la enzima de conversion de la angiotensina utilizando oxido de magnesio.
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
HU226950B1 (en) 1999-11-03 2010-03-29 Richter Gedeon Nyrt The magnesium salt of enalapril and antihypertensive pharmaceutical composition containing it
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2357982A1 (fr) 2001-09-28 2003-03-28 Bernard Charles Sherman Compositions solides contenant du ramipril
EP1467717A1 (fr) 2002-01-15 2004-10-20 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables comprenant un(des) inhibiteur(s) de l'enzyme de conversion
ITMI20020731A1 (it) * 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
WO2004064834A1 (fr) 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Losartan amorphe co-precipite et posologies comprenant celui-ci
WO2004064809A1 (fr) 2003-01-22 2004-08-05 Sandoz Ag Composition pharmaceutique solide comprenant du ramipril
AU2003300692A1 (en) 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
WO2005070398A2 (fr) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Compositions pharmaceutiques de candesartan cilexetil stabilisees par des co-solvants
EP1711168A2 (fr) 2004-01-23 2006-10-18 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales de candesartan cilexetil
WO2005084648A1 (fr) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Compositions pharmaceutiques comprenant du candesartan cilexetil
WO2006135415A2 (fr) 2004-09-08 2006-12-21 University Of Florida Research Foundation, Inc. Micelles et nanoemulsions pour le traitement prophylactique et reactif de l'atherosclerose
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
ZA200704767B (en) 2004-11-05 2008-08-27 King Pharmaceuticals Res & Dev Stabilized individually coated ramipril particles, compositions and methods
WO2006076097A2 (fr) 2004-12-07 2006-07-20 Nektar Therapeutics Preparation non cristalline stable contenant du losartan
EP1674080A1 (fr) 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant du valsartan
US20070036843A1 (en) 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
EP1865779A4 (fr) * 2005-03-21 2008-06-04 Vicus Therapeutics Spe 1 Llc Compositions et procedes permettant d'ameliorer la cachexie
GR1006875B (el) 2005-06-30 2010-07-12 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
WO2007103557A2 (fr) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Revêtement de capsules avec des ingrédients pharmaceutiques actifs
US20070281000A1 (en) 2006-06-02 2007-12-06 Michael Fox Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
WO2008001184A2 (fr) 2006-06-26 2008-01-03 Emcure Pharmaceuticals Limited Composition solide
US20100035955A1 (en) 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
EP2066649A1 (fr) 2006-07-28 2009-06-10 KRKA, tovarna zdravil, d.d., Novo mesto Procédé de préparation de formes amorphes et cristallines de candésartan cilexétil par chromatographie sur colonne
US20080152717A1 (en) 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
EP1952806A1 (fr) 2007-02-01 2008-08-06 Helm AG Procédé de préparation des produits d'absorption de candesartan
EP1997479A1 (fr) 2007-05-31 2008-12-03 Helm AG Formulations stabilisées contentant du candesartan cilexetil amorphe pour l'administration orale
UA102477C2 (en) * 2008-01-10 2013-07-10 Такеда Фармасьютикал Компани Лимитед Capsule composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011060945A2 *

Also Published As

Publication number Publication date
ES2364011B1 (es) 2013-01-24
AU2010321248A1 (en) 2012-06-07
RU2012122886A (ru) 2013-12-27
MX2012005744A (es) 2012-12-05
JP2013511480A (ja) 2013-04-04
AR079428A1 (es) 2012-01-25
WO2011060945A2 (fr) 2011-05-26
TW201141469A (en) 2011-12-01
BR112012011902A2 (pt) 2017-10-10
CA2781434A1 (fr) 2011-05-26
CN102711735A (zh) 2012-10-03
WO2011060945A3 (fr) 2012-01-19
ES2364011A1 (es) 2011-08-23
IL219874A0 (en) 2012-07-31
KR20120117986A (ko) 2012-10-25

Similar Documents

Publication Publication Date Title
WO2011060945A2 (fr) Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires
US11207273B2 (en) Method of making an L-menthol dosage form
EP1803440B1 (fr) Formulation pharmaceutique comprenant des microcapsules de statines en suspension dans des esters alkyliques d'acides gras polyinsatures (pufa)
DK169987B1 (da) Oralt indgiveligt farmaceutisk præparat, der som aktiv bestanddel indeholder en syrelabil forbindelse eller et alkalisalt heraf, samt en fremgangsmåde til fremstilling af præparatet
CA2520660C (fr) Forme posologique solide s'administrant par voie orale qui contient des microcapsules sans soudure
WO2008084504A2 (fr) Composition pharmaceutique d'inhibiteurs du récepteur de l'angiotensine ii
JP2002516270A (ja) リポ酸の制御放出
RS55786B1 (sr) Oralna formulacija za terapiju kardiovaskularnih bolesti
EP1515704B1 (fr) Microcapsules pour la liberation retardee et controlee du perindopril
EP1893181A1 (fr) Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2011060943A1 (fr) Formulations pharmaceutiques contenant des capsules de substance active bêta-bloquante et des esters d'acides gras polyinsaturés
EP4212149A1 (fr) Formes galéniques orales de sel acido-labile et procédés et utilisations associés
WO2006087395A1 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2882259A1 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
IE20080345A1 (en) A pharmaceutical composition
KR20040095521A (ko) 벤즈이미다졸 유도체의 경구용 제제

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/41 20060101ALI20130606BHEP

Ipc: A61K 31/401 20060101AFI20130606BHEP

Ipc: A61K 31/4184 20060101ALI20130606BHEP

Ipc: A61K 31/404 20060101ALI20130606BHEP

Ipc: A61K 9/50 20060101ALI20130606BHEP

Ipc: A61K 9/16 20060101ALI20130606BHEP

Ipc: A61K 9/48 20060101ALI20130606BHEP

INTG Intention to grant announced

Effective date: 20130620

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176021

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131031